STUDIES ON MUSTARD-STIMULATED PROTEASES AND INHIBITORS IN HUMAN EPIDERMAL KERATINOCYTES (HEK): DEVELOPMENT OF ANTIVESICANT DRUGS

Similar documents
Final Performance Report. Contract # FA C-0006: Hearing Protection for High-Noise Environments Period of Performance: Oct 01, 2007 Nov 30, 2009

Peng Zhang 1, Michelle Yueqin Chen 1, Diana Caridha 1, William J. Smith 2 & Peter K. Chiang 1

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

INTENSITY REDISTRIBUTION FOR MILTICONJUGATE ADAPTIVE OPTICS (Postprint)

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

2010 Annual report. Principle Investigator: Dr. John W. Frost. Draths Corporation. ONR Award Number: N

Long-Term Health Effects of Embedded Depleted Uranium

Utility of respiratory vaccination with recombinant subunit vaccines for protection against pneumonic plague.

Fort Detrick, Maryland

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

La Jolla, CA Approved for Public Release; Distribution Unlimited

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

Award Number: W81XWH

Report Documentation Page

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

ABSTRACT INTRODUCTION

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

A nonhuman primate model for aerosol infection with western equine encephalitis viruses

Approved for public release; distribution unlimited

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

712CD 75 TH MORSS CD Cover Page

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

Detection of Prostate Cancer Progression by Serum DNA Integrity

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

TITLE: A Role of Plasminogen in Promoting the Immune Escape in Small Cell Lung Cancer. PRINCIPAL INVESTIGATOR: Vera Levina, PhD. Pittsburgh, PA 15213

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

TRAUMATIC BRAIN INJURY: SAME OR DIFFERENT. Kimberly Meyer, ACNP-BC, CNRN

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

CONTRACTING ORGANIZATION: University of Southern California Los Angeles, CA 90033

60th Medical Group (AMC), Travis AFB, CA

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

Correlation Between The System Of Values And The Stressful Factors (Anxiety Level) Among The Group Of Georgian Soldiers

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine, New York, NY 10029

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

Award Number: W81XWH

Musculoskeletal Health and Injury Prevention

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

NAVSUP INITIATIVES FOR HEALTH & READINESS

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: Synthetic Lethal Gene for PTEN as a Therapeutic Target. PRINCIPAL INVESTIGATOR: Kounosuke Watabe, Ph.D.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer

Pandemic Influenza: Appropriations for Public Health Preparedness and Response

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

TITLE: Crosstalk Between Cancer Cells and Bones Via the Hedgehog Pathway Determines Bone Metastasis of Breast Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

21 st Century Military Nutrition: Considerations & Approaches

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Anti-Viral Prophylaxis Target Product Profile Guidelines

Christopher R. Erbes, PhD Melissa A. Polusny, PhD Minneapolis VA Medical Center and University of Minnesota Medical School

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

Tactical Checkpoint: Hail/Warn Suppress/Stop Target Behavioral Response Laboratory

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

CONTRACTING ORGANIZATION: Rush University Medical Center Chicago, IL 60612

Vitamin D3 and Vitamin D3 Analogs as Protectants Against the Cardiotoxicity of Chemotherapeutic Agents Utilized in the Treatment of Breast Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Transcription:

STUDIES ON MUSTARD-STIMULATED PROTEASES AND INHIBITORS IN HUMAN EPIDERMAL KERATINOCYTES (HEK): DEVELOPMENT OF ANTIVESICANT DRUGS Xiannu Jin 1, Radharaman Ray 2, Guang Xu 1 and Prabhati Ray 1 1 Department of Biology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910 and 2 Biochemical Pharmacology Branch, Pharmacology Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010 ABSTRACT Protease stimulation in HEK due to mustard (sulfur mustard, SM; nitrogen mustard, NM) exposure is well established. However, the specific protease(s) stimulated by mustard and the protease substrates remain to be determined. In this study, we observed that mustard stimulates several proteases, and the epidermal-dermal attachment protein laminin-5 is one of the substrates. In mustard-exposed skin, laminin-5 degradation results in the detachment of the epidermis from the dermis and, therefore, vesication. We utilized gelatin zymography, Western blotting, and immuno-fluorescence staining techniques to study the mustard-stimulated proteases and laminin-5 degradation in HEK. Two major protease bands (64 kda and 72 kda) were observed by zymography in mustard-exposed cells. Addition of serine protease inhibitors (50 µm ICD 2812 or 1 mm PMSF), the metalloprotease inhibitor 1, 10- phenanthroline (1 mm), or the caspase inhibitor Z-VAD-FMK (10 µm) to cells prior to SM exposure decreased the mustard-stimulated protease bands (zymography), and completely prevented mustardinduced laminin-5 degradation (Western blotting, immuno-fluorescence). In conclusion, our results in the HEK model indicate that (a) mustard stimulates multiple proteases in the skin, and (b) protease inhibitors are prospective vesicant countermeasures.

Report Documentation Page Form Approved OMB No. 0704-0188 Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. 1. REPORT DATE 16 NOV 2004 2. REPORT TYPE N/A 3. DATES COVERED - 4. TITLE AND SUBTITLE Studies On Mustard-Stimulated Proteases And Inhibitors In Human Epidermal Keratinocytes (Hek): Development Of Antivesicant Drugs 5a. CONTRACT NUMBER 5b. GRANT NUMBER 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Department of Biology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) 12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited 11. SPONSOR/MONITOR S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES See also ADM001849, 2004 Scientific Conference on Chemical and Biological Defense Research. Held in Hunt Valley, Maryland on 15-17 November 2004., The original document contains color images. 14. ABSTRACT 15. SUBJECT TERMS 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT UU a. REPORT unclassified b. ABSTRACT unclassified c. THIS PAGE unclassified 18. NUMBER OF PAGES 6 19a. NAME OF RESPONSIBLE PERSON Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std Z39-18

INTRODUCTION Protease stimulation in epidermal keratinocytes is believed to be one of the mechanisms of vesication (skin blister formation) due to the chemical warfare agent sulfur mustard (SM, bis-(2- chloroethyl) sulfide). However, the specific protease(s) stimulated by mustard and the protease substrates remain to be determined. Smith et al. (1) and Mol et al. (2) reported mustard stimulation of serine protease and metalloprotease, respectably in skin cells in vitro. Mustard-stimulated proteases cause the separation of the epidermis from the dermis by degrading attachment proteins such as laminin-5. Petrali et al. (Petrali, J. P., USAMRICD, APG, MD, personal communication) reported that laminin-5 is affected during pathologies associate with SM exposure. Therefore, in this study, we utilized gelatin zymography, Western blotting, and immuno-fluorescence staining techniques to study the mustard (SM, nitrogen mustard (NM)) stimulated proteases and laminin-5 degradation in HEK. The purpose of this research was to obtain new knowledge regarding the specific mustard-stimulated proteases, their functions, and inhibitors, so that a protease inhibitor-based antivesicant approach could be developed. MATERIALS AND METHODS Materials: HEK, human keratinocyte growth supplement were purchased from Cascade Biologics. Anti-laminin-5 α3, β3, γ2 polycolonal antibodies were from Santa Cruz. Chromozym TRY (serine specific substrate), 1, 10- phenanthroline, PMSF, and E-64 were from Roche. Coomassie blue R- 250 was from Sigma. Cell culture: Sulfur mustard and nitrogen mustard treatment-nhek cultures were initiated in basal media from frozen stock (passage 2) using 0.2 x 10 6 cells per 75 cm 2 plastic tissue culture flaks. Approximately 80% confluent cultures were subcultured to passage 3 to be used in the experiments. Exposure of cell with 300 µm sulfur mustard was done at USAMRICD, APG, MD. Zymography: Electrophoretic gelatin zymography was conducted as described by Heussen and Dowdle (3). Cell lysates were prepared at 16 hours after mustard exposure and in Mammalian Protein Extraction Reagent from Pierce. Protein concentration was determined by the BCATM protein assay described by Pierce. Cell lysates were normalized to equal protein concentrations. A 50 µg aliquot of each sample was lyophilized and mixed with 20 µl Tris-Glycine SDS sample buffer (2X) in the absence of any reducing agent, and incubated for 10 minutes at room temperature. The samples were electrophoresed on 10% polyacrylamide gels co-polymerized with 1 mg/ml gelatin (Invitrogen). After electrophoresis, the gels were incubated in zymogram renaturing buffer (Invitrogen) containing 2.5% Triton x100 with gentle agitation for 30 minutes at room temperature and then incubate in zymogram developing buffer (Invitrogen) for 30 minutes followed by replacing with fresh zymogram developing buffer and incubation at 37 0 C overnight. After incubation, the gels were stained with 0.5% Coomassie Brilliant Blue R-250 (Sigma) and de-stained with de-staining solution (40% methanol, 10% acetic acid in distilled water). Protease activity was detected as a clear band against a dark blue background of Coomassie-Blue R-250 stained gelatin. For inhibition studies, one of 1 mm of 1, 10 phenanthroline, 1 mm of PMSF, 10 µm of Z-VAD-FMK, and 100 µm of E-64 were added to flasks followed by 300µM sulfur mustard treatment. Elution of gel band was done by using the Bio-Rad Model 422 electroeluter. Chromozym TRY assay: Protease activity in electroeluted samples was assayed according to Cowan et al. (4) using chromozym TRY substrate. Western blot analysis: HEK lysate or medium was used and Western blotting was done using laminin-5 γ2 ployclonal antibody. 2

Immunofluorescence staining: Lamini-5 distribution and degradation were determined by an immunofluorescence staining using laminin-5 γ2 primary antibody. Rhodamine-conjugated secondary antibody for laminin-5 γ2 for 1 hour at room temperature and then washed with PBS 3 times at 5 minutes intervals. Slides were mounted with mounting solution (SIGMA). RESULTS AND DISCUSSION Protease bands in zymogram analysis: Gelatin zymogram of the unexposed HEK control group demonstrated that small amounts of protease were present, mainly as 72 kda and 64 kda. We observed an increase in 72 kda and 64 kda protease band due to mustard (figure 1). The 72 kda band from SM treated cell extract was cut and electroeluted. The 72 kda band showed increased SM stimulated protease activity by the Chromozym TRY method compared to untreated control (figure 2). Protease inhibitor study: Addition of the serine protease inhibitor ICD 2812 (50 µm), phenylmethylsulfinyl fluoride (PMSF, 1mM), and pan-caspase inhibitor Z-VAD-FMK (10 µm) to HEK prior to SM exposure decreased the SM stimulated 72 kda band as detected by zymography. Addition of metalloprotease inhibitor 1, 10-phenanthroline (1 mm), decreased the 64 kda protease band in SMexposed HEK (figure 3). The cysteine protease inhibitor E-64 (100 µm) was ineffective. 3

Protection of SM-induced laminin-5 degradation by protease inhibitors: Laminin-5 degradation was detected with 300 µm sulfur mustard and 300 µm nitrogen mustard treatment in HEK. The protection of laminin-5 degradation was found with addition of the serine protease inhibitor PMSF, or pan-caspase inhibitor Z-VAD-FMK. The metalloprotease inhibitor 1, 10-phenanthroline protected against laminin-5 degradation due to 300 µm SM (16 hour) (figure 4). Immuno-fluorescence staining with antilaminin 5 γ2 antibody revealed degradation of laminin-5 γ2 with 300 µm nitrogen mustard and the degradation of laminin 5 γ2 due to 300 µm nitrogen mustard was protected with the serine protease inhibitor PMSF and the metalloprotease inhibitor 1, 10-phenanthroline. Addition of the pan-caspase inhibitor Z-VAD-FMK also protected the degradation of laminin-5 γ2 (figure 5). However, the cysteine protease inhibitor E-64 (100 µm) did not protect against degradation of laminin-5 γ2. 4

In this study, three types of proteases induced by SM in HEK have been identified and characterized. Further analysis will be required to determine their physiological and pathological functions. CONCLUSION SM stimulates multiple types of proteases: Serine protease, metalloprotease, and caspases. SM stimulated protease degrades laminin-5, an epidermal-dermal attachment protein relevant to vesicantion. SM-induced laminin-5 degradation is partially prevented by pretreatment of HEK with inhibitors of serine protease (PMSF), metalloprotease (1, 10-phenanthroline), and caspases (Z-VAD-FMK), but not the prototype cysteine protease inhibitor (E-64). These results suggest a role of apoptosis in SM-induced laminin-5 degradation and, therefore, vesication. These results also suggest that protease inhibitors may be prospective antivesicant drugs. REFERENCES 1. Smith et al. Cell Biol. and Toxicol, 7, 239, 1991 2. Mol et al. TG004, Proceedings, 1999 3. Heussen and Dowdle. Anal. Biochem., 102(1),196-202, 1980 4. Cowan et al. Cell Biol. and Toxicol, 7(3), 239-348, 1991 5

6